The U.S. Food and Drug Administration has recently announced that the lifesaving allergy treatments, EpiPen and Mylan generic epinephrine auto-injectors, are on a “spot shortage.” This means that numerous large and small pharmacies across the country are on backorder of these lifesaving supplies. Anyone who is prescribed these medications must seek alternative options by talking with their doctors and pharmacies to have a backup plan for emergency situations. To keep track of the latest updates in regards to this medication, it’s recommended to follow and connect with the Allergic Living and FDA social media pages for the most current information.
This article was originally published by the Sun Sentinel. To read more responses from South Florida 100 participants, please visit: SunSentinel.com/100.